Study hammers last nail in the coffin for Bayer's Trasylol
New study findings caused Bayer to begin withdrawing supplies of its antifibrinolytic drug, Trasylol (aprotinin), from the US market.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.